Maxime is General Partner in the fund. He brings his vast expertise as a serial entrepreneur to the AmorChem team. This has been very valuable given the fund’s company creation focus. In fact, he initially became part of the AmorChem family in 2016 when he was brought on as the founding CEO of Mperia Therapeutics, AmorChem’s first spin-out. Subsequently, he played a leading role in the creation and management of Corbin Therapeutics, SemaThera, Inversago Pharma and MyX Therapeutics. He is also an active contributor to the Quebec biotech ecosystem through his participation and leadership in Montreal InVivo committees, in addition to being adjunct professor of the Pharmacy School at the University of Montreal.
Before joining AmorChem, Maxime played different drug development roles in local biotech companies, namely Ecopia Biosciences (became Thallion Pharma, acquired by Bellus Health), Bioxalis Medica (acquired by Procyon) and Labopharm (acquired by Paladin Labs/Endo). In 2008, he launched his first start-up, Nuvector, where its key asset reached Phase 2 trial with BiolineRx. He followed this in 2011 with the starting-up of gIcare pharma, for which he raised overall $10M from local and European investors. In addition, Maxime spent some time as entrepreneur-in-residence at Univalor, expanding his expertise in technology transfer and licensing. He holds a PhD in chemistry from Laval University and performed a postdoctoral fellowship at Stanford University. In addition, he completed a joint Executive MBA at UQÀM and Université Paris-Dauphine.